Posted by Michael Wonder on 30 Apr 2026
ICER releases evidence report on treatment for narcolepsy
29 April 2026 - Oveporexton provides a net health benefit compared to currently available treatments; therapy would be cost effective if priced between $50,400 - $59,400/year
The ICER today posted its revised evidence report assessing the comparative clinical effectiveness and value of oveporexton (Takeda) for narcolepsy type 1.
